14,020 AbbVie Inc. $ABBV Shares Acquired by Sapient Capital LLC

Sapient Capital LLC grew its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 7.1% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 210,256 shares of the company’s stock after purchasing an additional 14,020 shares during the quarter. AbbVie makes up approximately 0.8% of Sapient Capital LLC’s holdings, making the stock its 19th biggest position. Sapient Capital LLC’s holdings in AbbVie were worth $55,001,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in ABBV. CoreCap Advisors LLC raised its stake in shares of AbbVie by 4.4% in the third quarter. CoreCap Advisors LLC now owns 21,893 shares of the company’s stock worth $5,727,000 after buying an additional 926 shares during the period. Artemis Investment Management LLP increased its holdings in AbbVie by 3.0% in the 3rd quarter. Artemis Investment Management LLP now owns 497,086 shares of the company’s stock worth $130,033,000 after acquiring an additional 14,495 shares in the last quarter. YHB Investment Advisors Inc. lifted its holdings in AbbVie by 0.3% during the third quarter. YHB Investment Advisors Inc. now owns 37,565 shares of the company’s stock valued at $9,827,000 after purchasing an additional 125 shares in the last quarter. Apella Capital LLC boosted its position in shares of AbbVie by 14.2% in the third quarter. Apella Capital LLC now owns 23,477 shares of the company’s stock worth $6,371,000 after purchasing an additional 2,912 shares during the period. Finally, Everhart Financial Group Inc. increased its stake in shares of AbbVie by 1.8% in the third quarter. Everhart Financial Group Inc. now owns 25,782 shares of the company’s stock worth $6,744,000 after purchasing an additional 454 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

Shares of ABBV stock traded up $0.84 during trading hours on Thursday, hitting $272.20. The stock had a trading volume of 5,492,274 shares, compared to its average volume of 6,424,160. The stock has a market capitalization of $480.92 billion, a price-to-earnings ratio of 76.89, a PEG ratio of 1.22 and a beta of 0.24. AbbVie Inc. has a one year low of $190.75 and a one year high of $274.94. The stock’s 50-day moving average price is $258.56 and its two-hundred day moving average price is $236.35.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same quarter last year, the business posted $2.97 EPS. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities research analysts predict that AbbVie Inc. will post 13.93 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Thursday, October 15th. AbbVie’s dividend payout ratio is currently 195.48%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA breakthrough designations bolster oncology prospects. AbbVie’s investigational telisotuzumab adizutecan (Temab-A/ABBV-400), a c-Met-directed antibody-drug conjugate, received two FDA Breakthrough Therapy Designations for colorectal cancer and non-small cell lung cancer. The designations may accelerate development and regulatory review while supporting the value of AbbVie’s growing ADC portfolio. AbbVie Temab-A FDA Breakthrough Therapy Designations
• Positive Sentiment: Strong Phase 3 lymphoma data adds another potential growth driver. AbbVie and Genmab reported that epcoritamab combined with R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The result could expand Epkinly’s commercial opportunity if confirmed and approved. AbbVie and Genmab Epcoritamab Phase 3 Results
• Positive Sentiment: Analysts raised their valuation estimates. JPMorgan increased its AbbVie price target to $300 from $285 and maintained an “overweight” rating. Cantor Fitzgerald also raised its target to $290 from $285 and assigned an “overweight” rating, signaling continued confidence in the company’s pipeline and earnings outlook.
• Neutral Sentiment: Recent operating momentum provides support: AbbVie’s latest reported revenue rose 10.2% year over year to $16.99 billion, while EPS exceeded consensus estimates. However, the stock’s elevated valuation—approximately 77 times earnings—leaves less room for disappointment.
• Negative Sentiment: Dividend sustainability remains a risk. Commentary highlighted a reported payout ratio above 190%, meaning dividends substantially exceed GAAP earnings. Although noncash items and adjusted earnings can distort this measure, investors may remain concerned about long-term dividend coverage and financial flexibility.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. UBS Group restated a “neutral” rating on shares of AbbVie in a research note on Tuesday. Sanford C. Bernstein restated a “market perform” rating and issued a $225.00 price objective (up from $203.00) on shares of AbbVie in a research report on Tuesday, June 23rd. Citigroup upped their price objective on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 15th. Rothschild & Co Redburn lifted their target price on AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Finally, Erste Group Bank raised shares of AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $276.64.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.06% of the company’s stock.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.